1 May 2011BiotechAshley Roughton

Patenting life

Our European patent system is self-financing, self-sufficient and almost self-legislating. It works on two, intertwined levels. It is complex, has its own courts, and perhaps, some may say, the very last thing we need is further legislative interest by a body that, until recently, has had little to do with patenting in Europe. Yet this is what the European Council and Parliament did when trying to legislate for patents and morality in 1998 via Directive 98/44/EC on the legal protection of biotechnological inventions—the Biotech Directive.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
11 November 2026   The parties granted each other the right to use their respective patented inventions in the field of infectious disease but are not obligated to make any payments in connection with the licences.
Biotech
28 October 2026   Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.
Biotech
23 October 2026   Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.